top of page
PONTIAC
A RANDOMIZED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6 INHIBITOR-BASED ENDOCRINE THERAPY AS FIRST-LINE THERAPY OF HR-POSITIVE AND HER2-LOW/ULTRALOW ADVANCED BREAST CANCER PATIENTS CLASSIFIED AS NON-LUMINAL SUBTYPE ACCORDING TO GENE EXPRESSION PROFILING.
HR-positive and HER2-low/Ultralow Advanced Breastc Cancer
II
200
Pending
Spain, Italy, France, Germany, Austria, Hungary, Belgium, Poland, Portugal, Netherlands, UK
Set-up
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE IS TO DEMONSTRATE THAT FIRST-LINE T-DXD COMPARED WITH CDK4/6I PLUS ENDOCRINE THERAPY IS SUPERIOR IN PROLONGING THE PROGRESSION FREE SURVIVAL IN PATIENTS WITH HR-POSITIVE, HER2-LOW ADVANCED BREAST CANCER CLASSIFIED AS NON-LUMINAL BY GENE EXPRESSION PROFILING.
PONTIAC AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME
bottom of page